共 74 条
[11]
Holle R(2009)Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity Clin Neuropharmacol 32 259-928
[12]
Greiner W(2017)Medical care of patients with spasticity following stroke : evaluation of the treatment situation in Germany with focus on the use of botulinum toxin Nervenarzt 88 919-2506
[13]
Konig HH(1998)A prospective community-based study of stroke in Germany—the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months Stroke 29 2501-2861
[14]
Bronnum-Hansen H(2013)Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study Stroke 44 2854-539
[15]
Davidsen M(2008)Prevalence of disabling spasticity 1 year after first-ever stroke Eur J Neurol 15 533-1426
[16]
Thorvaldsen P(2012)Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type a: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial Toxins 4 1415-iiv
[17]
Danish MSG(2010)BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type a Health Technol Assess 14 iii-2020
[18]
Dressler D(2010)Occurence and clinical predictors of spasticity after ischemic stroke Stroke 41 2016-257
[19]
Rychlik R(2005)Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity J Rehabil Med 37 252-513
[20]
Kreimendahl F(2014)Functional goal achievement in post-stroke spasticity patients: the BOTOX(R) economic spasticity trial (BEST) J Rehabil Med 46 504-522